Last reviewed · How we verify

yangjie — Portfolio Competitive Intelligence Brief

yangjie pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PS PS marketed opioid mu-opioid receptor Pain management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Cari Health Inc. · 1 shared drug class
  3. Cedars-Sinai Medical Center · 1 shared drug class
  4. Depomed · 1 shared drug class
  5. Mundipharma Pharmaceuticals B.V. · 1 shared drug class
  6. Norwegian University of Science and Technology · 1 shared drug class
  7. St. Olavs Hospital · 1 shared drug class
  8. Talphera, Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for yangjie:

Cite this brief

Drug Landscape (2026). yangjie — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/yangjie. Accessed 2026-05-14.

Related